Capital InfusionThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.
Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.
Stock Repurchase PlanOramed announced that its Board of Directors has authorized a common stock repurchase plan allowing for buy-back of up to $20M of its common stock.